Toronto, Ontario – February 9, 2018
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations for the safe and effective destruction of various cancers, announced today that the sixth patient in a nine patient Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) was enrolled and treated on February 7, 2018, using the Company’s anti-cancer technology.
The Study is being used to evaluate the Company’s lead PDC drug for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue). The Study also includes an exploratory endpoint of efficacy; however, this will not be a determining factor in the success or failure of the Study.
Three patients have been enrolled and treated at the maximum recommended starting dose of 0.35 mg/cm2 and have successfully achieved the primary, secondary and exploratory endpoints at 90 days post treatment.
Three patients have been enrolled and treated at the therapeutic dose of 0.70 mg/cm2, with patient 4 successfully achieving the primary, secondary and exploratory endpoints at 90 days post treatment.
Patients 5 and 6 will be evaluated for the primary, secondary and exploratory endpoints at 90 days post treatment, in April 2018 and May 2018, respectively.
An additional three patients remain to be enrolled and treated at the therapeutic dose to complete the Study.
The Company plans to commence a multi-center Phase II NMIBC clinical study, in Canada, the United States and internationally with a primary endpoint of efficacy, subject to regulatory approvals.
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTCQX) is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations for the safe and effective destruction of various cancers. The Company in its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser technology for the treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint conditions.
Additional information is available at www.theralase.com and www.sedar.com
This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com